It is a cold, hard fact, that lung disease affecting an ever growing sector of the population today. Nearly 20 million Americans suffer from asthma and the disease can lead to lung cancer sufferers, which predispose a quarter-million new victims each year strike. The increased risk of lung with asthma who have never smoked, supports a direct correlation between asthma and lung. However, there does not exist a simple, reliable method to diagnose diseasethe human lung tissue early in their development. That is, until a recent study lead by the Cancer Prevention & Cure laboratory in San Antonio, TX to a discovery that everything is changed out.
The purpose of this study was to the panels of serum biomarkers to distinguish and recognize asthma to identify non-small cell lung cancer. The study identified several new panels of biomarkers (patent pending), the stratification and correctly classify the physiological state of a subject withRelation with non-small cell lung cancer and asthma. Simply put, their studies immediately revolutionized the way lung cancer is screened for and detected. Even more amazing is that all of this CPC detected by simple testing a patient's blood.
"Most lung cancers are discovered too late in terms of disease development, and the cases are quite serious before they are diagnosed correctly," said Robert Streeper, a study of school principals. "From the patient's perspective, theability to distinguish between a condition such as asthma and lung cancer is enormous. "
While this approach may sound like common sense in theory, it is really groundbreaking in the way CPC employs a proprietary panel that controls several blood biomarkers as indicators of cancer, and therefore has an exponentially more accurate diagnostic tool than previous one biomarker testing approaches. The findings support a multi-strategy marker for the diagnosis of non-small cell lung cancerease by measuring the expression of groups of biomarkers for early detection of disease through simple blood tests. The biomarkers may also characterize the progression of the disease, to differentiate between pathologies and monitoring patient responses to various drug therapies.
CT-scans - the current primary lung cancer diagnostic tool - are not only expensive, but are controversial because of the potentially dangerous levels of radiation they expose to a patient. TheResults can last longer, too, and can usually only see in full cases of cancer where treatment is too late. CPC's blood test is not only much cheaper than conventional CT scans, but provides immediate results and is much less invasive and safer diagnostic technology in general.
CPC's groundbreaking discovery is already referred to, copied and used for the study of other cancers such as ovarian and testicular cancer, by other laboratories and researchCompanies.
CPC would like to pre-screen at-risk patients who test their blood, whether their panel fits the biomarker profile, and when it does, they refer ten other diagnosis. 'Our goal, "Streeper said," is the form of a partnership with a large clinical services and the technology of. "
Groundbreaking as it is, not the effects of frontier research CPC is to stop not only in cancer diagnosis, Streeper said that they also found that men and women, lung cancerPatients are very different in terms of their biochemical profiles. Such a discovery is not only important from a diagnostic standpoint, but also has implications that should, perhaps, the treatments and tests for men and women differ as well. This also raises another question to the medical profession, in relation to other cancers in men and women - their different biochemical markers as well?
"No one knows. No one has ever published a study which, like" Streeper pointsout, which means that the CPC important diagnostic Ripple could pave the way each type of cancer detected and treated will change in the big pond of the future medical means.
Thanks To : cheap canon digital camera